Literature DB >> 12695018

5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties.

N Kaiser1, A Kimpfler, U Massing, A M Burger, H H Fiebig, M Brandl, R Schubert.   

Abstract

Vesicular phospholipid gels (VPG), i.e. highly concentrated liposomal dispersions, are suitable for entrapping substances such as anticancer drugs with particular high encapsulation efficiencies (EE). We prepared different formulations of VPG with 30% (w/w) lipid containing 5-fluorouracil (5-FU) by high pressure homogenization and analysed their EE and drug release. Using mixtures of hydrogenated soy phosphatidylcholine and cholesterol with molar ratios ranging from 55/45 to 75/25, a decreasing amount of cholesterol correlated with an increasing EE, which is probably due to a reduced amount of smaller vesicles and number of lamellae. Using a 5-FU solution of pH 8.6 for VPG preparation, an EE of approximately 40% was found after redispersion of the gel to a liposomal dispersion and separation of free drug from liposomal drug by size exclusion chromatography. The reduced EE for preparations with lower pH values was attributed to a fast initial drug release due to the increased drug lipophilicity below the pK(a) value of 8. After redispersion of a VPG of pH 8.0, an initially faster release of about a third of the entrapped drug was found during the first 20 min, followed by stable entrapment over many hours. The rapid initial release may be due to the portion of liposomes smaller than 40 nm in diameter, determined by photon correlation spectroscopy. Cryo electron microscopic pictures show a lentil-like shape of these small liposomes. The membrane defects on the edges are probably the reason for the very high initial drug release rate. The half-life time of the release of 5-FU from intact FU-VPG at both pH 7.4 and 8.0 was found to be in the order of 4-5 h and the kinetics are typical for matrix-controlled drug diffusion. The in vitro data of 5-FU loaded VPG suggest their applicability as implants with controlled release properties or, after redispersion, as intravenously injected liposomal formulations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695018     DOI: 10.1016/s0378-5173(03)00069-3

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.

Authors:  Kathryn M Camacho; Stefano Menegatti; Douglas R Vogus; Anusha Pusuluri; Zoë Fuchs; Maria Jarvis; Michael Zakrewsky; Michael A Evans; Renwei Chen; Samir Mitragotri
Journal:  J Control Release       Date:  2016-03-24       Impact factor: 9.776

2.  PEGylated Lipova E120 liposomes loaded with celecoxib: in-vitro characterization and enhanced in-vivo anti-inflammatory effects in rat models.

Authors:  Vivek Dave; Ashish Gupta; Priyanka Singh; Kajal Tak; Swapnil Sharma
Journal:  J Biosci       Date:  2019-09       Impact factor: 1.826

3.  In vivo distribution of 5-Fluorouracil after peritumoral implantation using a biodegradable micro-device in tumor-bearing mice.

Authors:  Na Zheng; Mingyao Zhou; Wen Lu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-11-22       Impact factor: 2.441

4.  Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery.

Authors:  Xiaoyu Chen; Wenhua Huang; Blenda Chi Wong; Linlin Yin; Yuen Fan Wong; Min Xu; Zhijun Yang
Journal:  Int J Nanomedicine       Date:  2012-02-28

Review 5.  Prevention and treatment of esophageal stenosis after endoscopic submucosal dissection for early esophageal cancer.

Authors:  Jing Wen; Zhongsheng Lu; Qingsen Liu
Journal:  Gastroenterol Res Pract       Date:  2014-10-16       Impact factor: 2.260

6.  The Advances and Challenges of Liposome-Assisted Drug Release in the Presence of Serum Albumin Molecules: The Influence of Surrounding pH.

Authors:  Danuta Pentak; Anna Ploch-Jankowska; Andrzej Zięba; Violetta Kozik
Journal:  Materials (Basel)       Date:  2022-02-20       Impact factor: 3.623

7.  An Inhalable Powder Formulation Based on Micro- and Nanoparticles Containing 5-Fluorouracil for the Treatment of Metastatic Melanoma.

Authors:  Kelly Cristine Zatta; Luiza A Frank; Luciano Antonio Reolon; Lucas Amaral-Machado; Eryvaldo S T Egito; Maria Palmira Daflon Gremião; Adriana Raffin Pohlmann; Silvia S Guterres
Journal:  Nanomaterials (Basel)       Date:  2018-01-30       Impact factor: 5.076

8.  Influence of spray-dried hydroxyapatite-5-fluorouracil granules on cell lines derived from tissues of mesenchymal origin.

Authors:  Tim Scharnweber; Catarina Santos; Ralf-Peter Franke; Maria Margarida Almeida; Maria Elisabete V Costa
Journal:  Molecules       Date:  2008-11-01       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.